RESEARCH MONOGRAPH · KDC-MN-052

Unifiram

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

41/100

Sunifiram's structural cousin with even thinner literature, mostly of medicinal chemistry interest

Unifiram (DM-232) is sunifiram's older sibling, also from the Manetti and Bartolini groups, with a furanoyl group where sunifiram has a methylsulfonyl. The behavioral pharmacology in rodents looks broadly similar (low-dose cognitive enhancement, AMPA-positive modulation, some glycine-site activity at NMDA), and the same medicinal chemistry program produced both compounds in the early 2000s.

The honest answer about unifiram is that the literature is essentially a subset of sunifiram's. The original publications mostly compared the two compounds head-to-head, sunifiram tended to look slightly more potent and reach the field more prominently, and modern interest in unifiram is correspondingly more limited. We're working from maybe a dozen published papers, most preclinical, with no human data of consequence.

What we can say structurally is that the piperazine scaffold with the furanoyl substituent puts it in a slightly different region of chemical space than sunifiram, and the pharmacological profile may differ at higher resolution than the standard behavioral assays can detect. The SAR work between the two compounds is actually informative for AMPA-PAM medicinal chemistry, even if neither has advanced clinically.

What we like: structural curiosity value, complementary tool to sunifiram for medicinal chemistry SAR work, and the same general low-dose potency in animal models that made sunifiram interesting in the first place.

What we dont like: human data is nonexistent, the published profile is thin enough that any specific claims about advantages over sunifiram are speculative, and the safety pharmacology hasnt been worked out in any detail.

Honestly, we havent worked with this compound enough to have strong opinions about subtle differences between it and sunifiram. The literature suggests theyre largely interchangeable for most behavioral pharmacology purposes.

Sourcing is genuinely a challenge. Fewer suppliers carry unifiram than sunifiram, characterization quality varies more, and reference standards are harder to find. HPLC and mass-spec verification are essentially required for any serious work. Some vendors sell mislabeled material, which is a real QC problem.

For research, this is a niche tool. If you've got a specific medicinal chemistry reason to compare the two compounds, fine. Otherwise, sunifiram is usually the cleaner starting point.

Evidence: 25
Mechanism: 50
Reliability: 40
Safety: 45
Sourcing: 45
Value: 40
Signal: 45
Staying power: 40

Plain-language summary Intrigue 38 / 100

Unifiram is closely related to sunifiram with similar AMPA receptor modulation. Both are research compounds with limited clinical evaluation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Piperazine-derived AMPA modulator

A close structural analog of sunifiram from the same Florence research program, differing in the carbonyl substituent on the piperazine.

Abstract

Unifiram (DM-232) is a close structural analog of sunifiram from the same University of Florence research program, differing in substituents on the piperazine carbonyl. The compound shows similar potency in rodent cognitive tests and similar mechanistic profile (presumed AMPA modulation, NMDA glycine facilitation). Like sunifiram, unifiram has no human clinical trial record, no Phase 1 safety data, and no formal toxicology beyond rodent studies. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled. The published literature is sparse; most references are to the same research group's structure-activity exploration of the piperazine ampakine class. Reported research dose ranges in the literature are similar to sunifiram (cited as 5 to 10 mg, unvalidated). The two compounds are essentially interchangeable in published cognitive endpoint assays at equivalent doses.

Mechanism of action

Same as sunifiram; AMPA potentiation with NMDA glycine site facilitation.

Reported research dose ranges

Reported research dose ranges in the literature span 5 to 10 mg (unvalidated).

References

Romanelli MN, et al. Sunifiram and unifiram: design and pharmacology. Bioorg Med Chem 2005.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-052

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Unifiram

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs